Trial Profile
A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2019
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors EMD Serono
- 05 Nov 2010 Actual end date (December 2007) added as reported by ClinicalTrials.gov.
- 05 Nov 2010 Actual end date (December 2007) added as reported by ClinicalTrials.gov.
- 05 Nov 2010 Actual end date (December 2007) added as reported by ClinicalTrials.gov.